Targeting the Proprotein Convertase Subtilisin/Kexin Type 9 for the Treatment of Dyslipidemia and Atherosclerosis
Open accessThe DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17018-9 · Cited by 12,026
Inflammation in atherosclerosis
Libby, P. (2002) · Nature · doi:10.1038/nature01323 · Cited by 8,315
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
Diabetes and Atherosclerosis: Epidemiology, Pathophysiology, and Management
Beckman, J. A., Creager, M. A., & Libby, P. (2002) · JAMA · doi:10.1001/jama.287.19.2570 · Cited by 2,724
Receptor-Mediated Endocytosis: Concepts Emerging from the LDL Receptor System
Goldstein, J. L., Brown, M. S., Anderson, R. G. W., Russell, D. W., & Schneider, W. J. (1985) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.01.110185.000245 · Cited by 1,600
Cohen, J., Pertsemlidis, A., Kotowski, I. K., Graham, R., Garcia, C. K., & Hobbs, H. H. (2005) · Nature Genetics · doi:10.1038/ng1509 · Cited by 1,381 · cited 1×
“Conversely, loss-of-function mutations of the PCSK9 gene were discovered and linked to low plasma LDL-C levels and a reduction of cardiovascular risk (7,8).”
BackgroundHorton, J. D., Shah, N. A., Warrington, J. A., Anderson, N. N., Park, S. W., Brown, M. S., & Goldstein, J. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1534923100 · Cited by 1,270
Seidah, N. G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Jasmin, S. B., Stifani, S., Basak, A., Prat, A., & Chrétien, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0335507100 · Cited by 1,191
Cited by
Macrophage‐mediated cholesterol handling in atherosclerosis
Chistiakov, D. A., Bobryshev, Y. V., & Orekhov, A. N. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12689 · Cited by 510
Wadhera, R. K., Steen, D. L., Khan, I., Giugliano, R. P., & Foody, J. M. (2016) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.11.010 · Cited by 306
Qi, Z., Hu, L., Zhang, J., Yang, W., Liu, X., Jia, D., Yao, Z., Chang, L., Pan, G., Zhong, H., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.046290 · Cited by 268
Colhoun, H. M., Ginsberg, H. N., Robinson, J. G., Leiter, L. A., Müller-Wieland, D., Henry, R. R., Cariou, B., Baccara-Dinet, M. T., Pordy, R., Merlet, L., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw292 · Cited by 172
“–10 Alirocumab is a fully human proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibody that lowers LDL-C levels by increasing the number of low-density lipoprotein receptors (LDLRs).(11) Alirocumab reduces LDL-C by up to 61% as monotherapy or in addition to statins, with or without other lipid-lower…”
BackgroundMolecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9)
Schulz, R., Schlüter, K.-D., & Laufs, U. (2015) · Basic Research in Cardiology · doi:10.1007/s00395-015-0463-z · Cited by 137
Self-citationInclisiran—New hope in the management of lipid disorders?
Dyrbuś, K., Gąsior, M., Penson, P., Ray, K. K., & Banach, M. (2020) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2019.11.001 · Cited by 120
Targeting RNA With Antisense Oligonucleotides and Small Interfering RNA in Dyslipidemias
Katzmann, J. L., Packard, C. J., Chapman, M. J., Katzmann, I., & Laufs, U. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.05.070 · Cited by 99
Self-citationPCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future
Shimada, Y. J., & Cannon, C. P. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv174 · Cited by 98
Kallend, D., Stoekenbroek, R., He, Y., Smith, P. F., & Wijngaard, P. (2022) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2022.01.001 · Cited by 73
Rubino, J., MacDougall, D. E., Sterling, L. R., Kelly, S. E., McKenney, J. M., & Lalwani, N. D. (2021) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2021.05.002 · Cited by 69
Effects of endurance training on serum lipids
Fikenzer, K., Fikenzer, S., Laufs, U., & Werner, C. (2018) · Vascular Pharmacology · doi:10.1016/j.vph.2017.11.005 · Cited by 67
Self-citationHegele, R. A., Gidding, S. S., Ginsberg, H. N., McPherson, R., Raal, F. J., Rader, D. J., Robinson, J. G., & Welty, F. K. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.306442 · Cited by 63
“Gain-of-function mutations in the PCSK9 gene cause autosomal-dominant hypercholesterolemia,73 whereas loss-of-function mutations are associated with lower LDL cholesterol and reduced CVD risk.21,74 Monoclonal antibodies (mAbs) against PCSK9 were recently approved in Europe and in North America.75 Alirocumab and evoloc…”
BackgroundGenetic architecture for human aggression: A study of gene–phenotype relationship in OMIM
Zhang‐James, Y., & Faraone, S. V. (2016) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32363 · Cited by 48
PCSK9: A Key Target for the Treatment of Cardiovascular Disease (CVD)
Sobati, S., Shakouri, A., Edalati, M., Mohammadnejad, D., Parvan, R., Masoumi, J., & Abdolalizadeh, J. (2020) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.2020.062 · Cited by 33
Safaeian, L., Mirian, M., & Bahrizadeh, S. (2022) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2020.1788605 · Cited by 32
Farnier, M., Colhoun, H. M., Sasiela, W. J., Edelberg, J. M., Asset, G., & Robinson, J. G. (2017) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2017.05.016 · Cited by 30
“This increases the number of LDL receptors on hepatocytes and promotes the removal of LDL-C from the circulation, thus lowering LDL-C levels.(15,16) Clinical trials of alirocumab, as a monotherapy or in combination with statins (with or without other lipid-lowering therapies [LLTs]), have demonstrated reductions in LD…”
BackgroundDurairaj, A., Sabates, A., Nieves, J., Moraes, B., & Baum, S. (2017) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-017-0556-0 · Cited by 27
Du, Y., Xi, M., Li, Y., Zheng, R., Ding, X., Li, X., Zhang, X., Wang, L., Xing, J., & Hong, B. (2023) · Phytomedicine · doi:10.1016/j.phymed.2022.154577 · Cited by 21
Wang, Z., Chen, X., Liu, J., Wang, Y., & Zhang, S. (2022) · Autoimmunity · doi:10.1080/08916934.2022.2051142 · Cited by 16
(2023) · PubMed Central · Cited by 16
MMP‐2 inhibits PCSK9‐induced degradation of the LDL receptor in Hepa1‐c1c7 cells
Wang, X., Berry, E., Hernandez-Anzaldo, S., Sun, D., Adijiang, A., Li, L., Zhang, D., & Fernandez-Patron, C. (2015) · FEBS Letters · doi:10.1016/j.febslet.2015.01.007 · Cited by 15
Metadata
- Authors
- Urban, D., Pöss, J., Böhm, M., & Laufs, U.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2013-10
- Volume
- 62
- Issue
- 16
- Pages
- 1401-1408
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2064328378
- Cited by
- 286
- References
- 76
- FWCI
- 28.74
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.